MedTrace Logo

SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT00504296 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2023-08-04

No results posted yet for this study

Summary

RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating patients with locally advanced or metastatic solid tumors.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

HDAC inhibitor SB939

SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

OTHER

immunologic technique

OTHER

laboratory biomarker analysis

OTHER

liquid chromatography

OTHER

mass spectrometry

OTHER

pharmacological study

Sponsors & Collaborators

  • S*BIO

    collaborator INDUSTRY

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Lillian L. Siu, MD, FRCPC · Princess Margaret Hospital, Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-14
Primary Completion
2010-04-22
Completion
2011-06-21

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504296 on ClinicalTrials.gov